Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

J. Remon Masip,B. Besse,S. Ponce Aix,A. Callejo, K. Al-Rabi,R. Bernabe Caro, L. Greillier,M. Majem Tarruella,N. Reguart Aransay,I. Monnet, S. Cousin,P. Garrido Lopez,G. Robinet,M. R. Garcia Campelo,A-C. Madroszyk Flandin,J. Mazieres, Y. Pretzenbacher, B. Fournier,A-M. C. Dingemans,R. Dziadziuszko

ANNALS OF ONCOLOGY（2022）

引用 12|浏览9

暂无评分

摘要

The serial monitoring of ctDNA T790M status in advanced EGFR-mutant non-small-cell lung cancer during treatment with first-generation EGFR inhibitors was feasible, and a molecular progression before RECIST PD led to an earlier switch to osimertinib in 17% of patients with satisfactory PFS and OS outcomes.

查看译文

关键词

EGFR-mutant,advanced non-small-cell lung cancer,ctDNA,liquid biopsy,molecular progression,osimertinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要